The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
HER2 persistence after treatment with T-DXd in breast and gastrointestinal cancers.
 
Joshua Z. Drago
Honoraria - Virology Education
Consulting or Advisory Role - AmMax Bio; AstraZeneca; Biotheranostics; GenagonTherapeutics; Intellisphere, LLC; NuProbe
Research Funding - AstraZeneca
 
Fresia Pareja
No Relationships to Disclose
 
Komal L. Jhaveri
Consulting or Advisory Role - Abbvie; AstraZeneca; Biotheranostics; BluePrint Medicines; Bristol-Myers Squibb; Daiichi Sankyo; Genentech; Gilead Sciences; Intellisphere; Jounce therapeutics; Lilly; Novartis; Pfizer; Sanofi; Scorpion Therapeutics; Seagen; Sun Pharma Advanced Research Company; Synthon; Taiho Oncology
Research Funding - ADC Therapeutics (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Context Therapeutics (Inst); Debiopharm Group (Inst); Genentech (Inst); Immunomedics (Inst); Lilly (Inst); Novartis (Inst); Novita Pharmaceuticals (Inst); Pfizer (Inst); Puma Biotechnology (Inst); VelosBio/Merck (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Genentech/Roche; Gilead Sciences; Intellisphere; Jounce Therapeutics; Lilly; Pfizer; Taiho Pharmaceutical
 
Elaine M. Walsh
Consulting or Advisory Role - DeciBio
 
Geoffrey Yuyat Ku
Consulting or Advisory Role - Apexigen; AstraZeneca/Daiichi Sankyo; Bristol-Myers Squibb; I-Mab; Merck Sharp & Dohme; Pieris Pharmaceuticals
Research Funding - Adaptimmune (Inst); Arog (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); CARsgen Therapeutics (Inst); Daiichi Sankyo (Inst); Merck (Inst); Oncolys BioPharma (Inst); Pieris Pharmaceuticals (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Aduro Biotech; AstraZeneca/MedImmune; Bristol-Myers Squibb; Merck Sharp & Dohme; Pieris Pharmaceuticals
 
Steven Brad Maron
Stock and Other Ownership Interests - Calithera Biosciences
Honoraria - Clarion Healthcare; Clinical Care Options; Medpage; Physicans' Education Resource; Practicing Clinician Exchange; Vindico Medical Education
Consulting or Advisory Role - Amgen; Bicara Therapeutics; Daichi Sankyo; Elevation Oncology; Novartis
Research Funding - Epic Sciences; Guardant Health (Inst)
 
Yelena Y. Janjigian
Stock and Other Ownership Interests - Rgenix
Consulting or Advisory Role - AmerisourceBergen; Arcus Biosciences; AskGene Pharma; AstraZeneca; Basilea Pharmaceutical; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Geneos; GlaxoSmithKline; Imedex; Imugene; Lilly; Lynx Health; Merck; Merck Serono; Mersana; Michael J. Hennessy Associates; Paradigm; Peerview; Pfizer; Phanes Therapeutics; Research to Practice; Rgenix; Seagen; Silverback Therapeutics; Zymeworks
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Cycle for Survival (Inst); Department of Defense (Inst); Fred's Team (Inst); Genentech/Roche (Inst); Lilly (Inst); Merck (Inst); NCI (Inst); Rgenix (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb Japan
Other Relationship - Axis Medical Education; Clinical Care Options; Research to Practice
 
Mark E. Robson
Consulting or Advisory Role - Change HealthCare
Research Funding - AstraZeneca (Inst); Merck (Inst); Pfizer (Inst); Zenith Pharmaceuticals (Inst)
Other Relationship - AstraZeneca; Clinical Care Options; Clinical Education Alliance; MJH Healthcare Holdings, LLC; MyMedEd; Pfizer; Physicans' Education Resource; Research to Practice
(OPTIONAL) Uncompensated Relationships - Artios; Daiichi Sankyo; Epic Sciences; Merck; Pfizer; Tempus; Zenith Pharmaceuticals
 
Jorge S. Reis-Filho
Leadership - Grupo Oncoclinicas
Stock and Other Ownership Interests - PAIGE.AI; Repare Therapeutics
Consulting or Advisory Role - Bain Capital Life Sciences; Genentech/Roche; Goldman Sachs; Invicro; Novartis; Paige.AI; Personalis; Repare Therapeutics; SAGA Diagnostics; Ventana Medical Systems; Volition RX
 
Shanu Modi
Honoraria - Daiichi Sankyo/Astra Zeneca; Seagen
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Genentech; GlaxoSmithKline; Lilly; Macrogenics; Puma Biotechnology; Seagen; Zymeworks
Research Funding - AstraZeneca (Inst); Daiichi Sankyo (Inst); Roche/Genentech (Inst); Seagen (Inst)
 
Pedram Razavi
Stock and Other Ownership Interests - Odyssey Biosciences
Honoraria - Daiichi Sankyo/Astra Zeneca; Pfizer
Consulting or Advisory Role - AstraZeneca; bioTheranostics; Epic Sciences; Guardant Health; Guardant Health; Inivata; Natera; Novartis; PAIGE.AI; Prelude Therapeutics; SAGA Diagnostics; Tempus
Research Funding - Archer (Inst); AstraZeneca (Inst); AstraZeneca (Inst); bioTheranostics (Inst); Epic Sciences (Inst); GRAIL (Inst); Guardant Health (Inst); Illumina (Inst); Novartis (Inst); Tempus (Inst)
 
Sarat Chandarlapaty
Stock and Other Ownership Interests - Odyssey Biosciences; Totus Medicines
Consulting or Advisory Role - AstraZeneca/MedImmune; Boxer Capital; Inivata; Lilly; Novartis; Paige.ai; Prelude Therapeutics; SAGA Diagnostics; Sanofi
Research Funding - Ambryx (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); Lilly (Inst); Novartis (Inst); Paige.ai (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Patent pending for (1) targeting mutant ER with ER PROTACS and (2) targeting CDK4/6 with CDK4/6 PROTACS (Inst)
Travel, Accommodations, Expenses - Novartis Institutes for BioMedical Research
Other Relationship - Peerview; Targeted Oncology; WebMD
(OPTIONAL) Uncompensated Relationships - Odyssey Biosciences; Totus Medicines